, Volume 74, Issue 16, pp 1947–1960 | Cite as

Clevidipine: A Review of Its Use for Managing Blood Pressure in Perioperative and Intensive Care Settings

  • Gillian M. KeatingEmail author
Adis Drug Evaluation


The ultrashort-acting dihydropyridine calcium channel antagonist clevidipine (Cleviprex®) has a rapid onset and offset of effect and reduces blood pressure (BP) by decreasing arteriolar resistance without affecting venous capacitance vessels. This article reviews the clinical efficacy and tolerability of intravenous clevidipine when used to manage BP in perioperative and intensive care settings, as well as summarizing its pharmacological properties. Intravenous clevidipine effectively treated preoperative and postoperative hypertension in patients undergoing cardiac surgery, according to the results of the randomized, multicentre, double-blind, phase III ESCAPE-1 and ESCAPE-2 trials. The randomized, open-label, multicentre, phase III ECLIPSE trials indicated that in terms of keeping systolic BP within the target range, clevidipine was more effective than nitroglycerin or sodium nitroprusside perioperatively and had similar efficacy to nicardipine postoperatively in cardiac surgery patients. In small, double-blind trials in patients undergoing coronary artery bypass graft surgery, perioperative clevidipine was noninferior to nitroglycerin, and postoperative clevidipine had similar efficacy to sodium nitroprusside. Noncomparative studies demonstrated that clevidipine provided rapid BP control in patients with acute neurological injuries (including intracerebral haemorrhage, subarachnoid haemorrhage and acute ischaemic stroke), and was not associated with ‘overshoot’ in the vast majority of patients. Intravenous clevidipine was generally well tolerated and was usually associated with no reflex tachycardia or only very modest increases in heart rate. In conclusion, intravenous clevidipine is a valuable agent for the management of BP in perioperative and intensive care settings.


Mean Arterial Pressure Acute Ischaemic Stroke Nicardipine Sodium Nitroprusside Target Blood Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The preparation of this review was not supported by any external funding. Gillian Keating is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.


  1. 1.
    Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst Pharm. 2004;61(16):1661–73.PubMedGoogle Scholar
  2. 2.
    Feneck R. Drugs for the perioperative control of hypertension: current issues and future directions. Drugs. 2007;67(14):2023–44.CrossRefGoogle Scholar
  3. 3.
    Weiss SJ, Longnecker DE. Perioperative hypertension: an overview. Coron Artery Dis. 1993;4(5):401–6.CrossRefGoogle Scholar
  4. 4.
    Aronson S, Dyke CM, Levy JH, et al. Does perioperative systolic blood pressure variability predict mortality after cardiac surgery? An exploratory analysis of the ECLIPSE trials. Anesth Analg. 2011;113(1):19–30.CrossRefGoogle Scholar
  5. 5.
    Awad AS, Goldberg ME. Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review. Vasc Health Risk Manag. 2010;6:457–64.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Sarafidis PA, Georgianos PI, Malindretos P, et al. Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs. 2012;21(8):1089–106.CrossRefGoogle Scholar
  7. 7.
    Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs. 2008;68(3):283–97.CrossRefGoogle Scholar
  8. 8.
    Ericsson H, Fakt C, Jolin-Mellgård Å, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999;47(5):531–8.CrossRefGoogle Scholar
  9. 9.
    The Medicines Company. Cleviprex (clevidipine) 0.5 mg/ml emulsion for injection: UK summary of product characteristics. 2013. Accessed 25 Sep 2014.
  10. 10.
    The Medicines Company. The Medicines Company launches new formulation of Cleviprex® (clevidipine) injectable emulsion (media release). 2011. Accessed 25 Sep 2014.
  11. 11.
    The Medicines Company. Cleviprex (clevidipine) injectable emulsion for intravenous use: US prescribing information. 2011. Accessed 25 Sep 2014.
  12. 12.
    Deeks ED, Keating GM, Keam SJ. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs. 2009;9(2):117–34.CrossRefGoogle Scholar
  13. 13.
    Nordlander M, Sjöquist P-O, Ericsson H, et al. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004;22(3):227–50.CrossRefGoogle Scholar
  14. 14.
    Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled Efficacy Study of Clevidipine Assessing its Preoperative Antihypertensive Effect in Cardiac Surgery-1. Anesth Analg. 2007;105(4):918–25.CrossRefGoogle Scholar
  15. 15.
    Kieler-Jensen N, Jolin-Mellgård Å, Nordlander M, et al. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand. 2000;44(2):186–93.CrossRefGoogle Scholar
  16. 16.
    Singla N, Warltier DC, Gandhi SD, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an Efficacy Study of Clevidipine Assessing its Postoperative Antihypertensive Effect in Cardiac Surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107(1):59–67.CrossRefGoogle Scholar
  17. 17.
    Ericsson H, Fakt C, Höglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol. 1999;55(1):61–7.CrossRefGoogle Scholar
  18. 18.
    Bekker A, Didehvar S, Kim S, et al. Efficacy of clevidipine in controlling perioperative hypertension in neurosurgical patients: initial single-center experience. J Neurosurg Anesthesiol. 2010;22(4):330–5.CrossRefGoogle Scholar
  19. 19.
    Smith WB, Marbury TC, Komjathy SF, et al. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension. Eur J Clin Pharmacol. 2012;68(10):1385–94.CrossRefGoogle Scholar
  20. 20.
    Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology. 2002;96(5):1086–94.CrossRefGoogle Scholar
  21. 21.
    Powroznyk AVV, Vuylsteke A, Naughton C, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol. 2003;20(9):697–703.CrossRefGoogle Scholar
  22. 22.
    Schwieler JH, Ericsson H, Löfdahl P, et al. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999;34(2):268–74.CrossRefGoogle Scholar
  23. 23.
    Ericsson H, Bredberg U, Eriksson U, et al. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000;92(4):993–1001.CrossRefGoogle Scholar
  24. 24.
    Ericsson H, Tholander B, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999;8(1):29–37.CrossRefGoogle Scholar
  25. 25.
    Vuylsteke A, Milner Q, Ericsson H, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth. 2000;85(5):683–9.CrossRefGoogle Scholar
  26. 26.
    Zhang JG, Dehal SS, Ho T, et al. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite H152/81. Drug Metab Dispos. 2006;34(5):734–7.CrossRefGoogle Scholar
  27. 27.
    Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110–21.CrossRefGoogle Scholar
  28. 28.
    Merry AF, Avery EG, Nussmeier NA, et al. Clevidipine compared with nitroglycerin for blood pressure control in coronary artery bypass grafting: a randomized double-blind study. Can J Anaesth. 2014;61(5):398–406.CrossRefGoogle Scholar
  29. 29.
    Aronson S, Levy JH, Lumb PD, et al. Impact of perioperative blood pressure variability on health resource utilization after cardiac surgery: an analysis of the ECLIPSE trials. J Cardiothorac Vasc Anesth. 2014;28(3):579–85.CrossRefGoogle Scholar
  30. 30.
    Aronson S, Dasta JF, Levy JH, et al. A cost analysis of the impact of a new intravenous antihypertensive in managing perioperative blood pressure during cardiac surgery. Hosp Pract. 2014;42(3):26–32.CrossRefGoogle Scholar
  31. 31.
    Graffagnino C, Bergese S, Love J, et al. Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial. Cerebrovasc Dis. 2013;36(3):173–80.CrossRefGoogle Scholar
  32. 32.
    Polderman KH, Bajus D, Varon J. Use of clevidipine (Cleviprex®) to control blood pressure (BP) in patients with intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) (abstract no. 323). In: 12th Annual Neurocritical Care Society Meeting; 11–14 Sep 2014; Seattle (WA).Google Scholar
  33. 33.
    Polderman KH, Bajus D, Varon J. IV clevidipine (Cleviprex®) rapidly controls blood pressure (BP) in acute ischemic stroke (AIS) (abstract no. 327). In: 12th Annual Neurocritical Care Society Meeting; 11–14 Sep 2014; Seattle (WA).Google Scholar
  34. 34.
    Polderman KH, Bajus D, Varon J. Clevidipine is safe and effective for blood pressure management in patients with acute neurological injuries (abstract). In: 27th Annual Congress of the European Society of Intensive Care Medicine; 27 Sep–1 Oct 2014; Barcelona.Google Scholar
  35. 35.
    Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010;30(5):515–28.CrossRefGoogle Scholar
  36. 36.
    van den Born BJH, Beutler JJ, Gaillard CAJM, et al. Dutch guideline for the management of hypertensive crisis: 2010 revision. Neth J Med. 2011;69(5):248–55.PubMedGoogle Scholar
  37. 37.
    Aronson S. Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials. Expert Rev Cardiovasc Ther. 2009;7(5):465–72.CrossRefGoogle Scholar
  38. 38.
    Ramos AP, Varon J. Current and newer agents for hypertensive emergencies. Curr Hypertens Rep. 2014;6(7):450.CrossRefGoogle Scholar
  39. 39.
    Getsios D, Wang Y, Stolar M, et al. Improved perioperative blood pressure control leads to reduced hospital costs. Expert Opin Pharmacother. 2013;14(10):1285–93.CrossRefGoogle Scholar
  40. 40.
    Mayer SA, Kurtz P, Wyman A, et al. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the studying the treatment of acute hypertension registry. Crit Care Med. 2011;39(10):2330–6.CrossRefGoogle Scholar
  41. 41.
    Manning L, Hirakawa Y, Arima H, et al. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol. 2014;13(4):364–73.CrossRefGoogle Scholar
  42. 42.
    Rodríguez-Yáñez M, Castellanos M, Freijo MM, et al. Clinical practice guidelines in intracerebral haemorrhage. Neurologia. 2013;28(4):236–49.CrossRefGoogle Scholar
  43. 43.
    Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108–29.CrossRefGoogle Scholar
  44. 44.
    Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefGoogle Scholar
  45. 45.
    Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council American Heart Association. Stroke. 2009;40(3):994–1025.CrossRefGoogle Scholar
  46. 46.
    Manning L, Robinson TG, Anderson CS. Control of blood pressure in hypertensive neurological emergencies. Curr Hypertens Rep. 2014;16(6):436.CrossRefGoogle Scholar
  47. 47.
    Pollack CV, Varon J, Garrison NA, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53(3):329–38.CrossRefGoogle Scholar
  48. 48.
    Peacock WF, Varon J, Ebrahimi R, et al. Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis. Blood Press. 2011;20(Suppl 1):20–5.CrossRefGoogle Scholar
  49. 49.
    Peacock WF, Varon J, Ebrahimi R, et al. Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis. Congest Heart Fail. 2010;16(2):55–9.CrossRefGoogle Scholar
  50. 50.
    Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure—A Pilot Study (PRONTO). Am Heart J. 2014;167(4):529–36.CrossRefGoogle Scholar
  51. 51.
    Tobias JD, Schechter WS, Phillips A, et al. Clevidipine for perioperative blood pressure control in infants and children undergoing cardiac surgery for congenital heart disease. J Pediatric Pharmacol Ther. 2011;16(1):55–60.Google Scholar
  52. 52.
    Tobias JD, Hoernschemeyer DG. Clevidipine for controlled hypotension during spinal surgery in adolescents. J Neurosurg Anesthesiol. 2011;23(4):347–51.CrossRefGoogle Scholar
  53. 53.
    Tobias JD, Allee J, Ramachandran V, et al. Clevidipine controls intraoperative blood pressure in an adolescent with renal failure. J Pediatr Pharmacol Ther. 2009;14(3):144–7.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Bettesworth JG, Martin DP, Tobias JD. Intraoperative use of clevidipine in a patient with Von Hippel-Lindau disease with associated pheochromocytoma. J Cardiothorac Vasc Anesth. 2013;27(4):749–51.CrossRefGoogle Scholar
  55. 55.
    Towe E, Tobias JD. Preliminary experience with clevidipine in the pediatric population. J Intensive Care Med. 2010;25(6):349–52.CrossRefGoogle Scholar
  56. 56.
    Tobias JD, Tulman DB, Bergese SD. Clevidipine for perioperative blood pressure control in infants and children. Pharmaceuticals. 2013;6(1):70–84.CrossRefGoogle Scholar
  57. 57.
    The Medicines Company. Assessment of efficacy, safety and dosing of clevidipine in pediatric patients undergoing surgery (PIONEER study) ( identifier NCT01938547) US National Institues of Health, 2014. Accessed 25 Sep 2014.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations